Skip to main content

Advertisement

Table 3 Cochrane Bone, Joint and Muscle Injury Group scores for all 32 RCTs.

From: Does a "Level I Evidence" rating imply high quality of reporting in orthopaedic randomised controlled trials?

Study Level of Evidence Cochrane Bone, Joint and Muscle Trauma Group reporting quality assessment score item (see below)
   A B C D E F G H I J K L
1 II-2 0 0 0 0 0 0 2 2 2 1 2 1
2 I-1b 1 1 2 2 0 0 2 2 2 2 2 2
3 I-1a 1 0 2 2 2 0 1 2 2 2 1 1
4 I-1a 1 1 0 2 0 0 2 2 2 2 1 1
5 II-2 2 1 0 0 0 0 0 2 2 2 2 2
6 I-1b 2 0 2 2 0 0 0 2 2 2 2 1
7 I-1a 1 0 0 2 0 0 2 2 2 2 2 0
8 I-1a 1 2 0 2 0 0 1 2 2 2 2 2
9 I-1a 2 0 0 2 0 0 1 1 2 2 2 2
10 I-1a 1 0 0 2 0 0 2 1 2 2 1 1
11 I-1b 1 0 2 0 0 0 2 1 2 2 1 1
12 I-1a 1 2 0 1 0 0 1 1 1 2 2 2
13 I-1a 2 0 1 2 0 0 0 1 2 2 1 1
14 I-1a 0 1 0 2 0 0 1 2 2 2 2 1
15 I-1a 2 1 0 2 0 0 1 2 2 2 2 1
16 I-1a 1 1 0 1 0 0 0 1 2 2 2 1
17 I-1b 0 0 0 0 0 0 0 2 2 2 1 1
18 I-1a 0 1 2 0 0 0 2 2 2 2 2 0
19 I-1a 2 1 2 2 0 0 2 2 2 2 2 2
20 I-1a 1 2 0 2 2 0 2 2 2 2 2 1
21 I-1a 1 0 2 2 0 0 2 2 2 2 2 2
22 I-1a 1 1 0 0 0 0 2 2 2 2 2 2
23 I-1a 2 2 0 2 0 0 2 2 2 2 2 2
24 I-1a 2 1 2 1 2 2 2 2 2 2 2 1
25 I-1b 0 2 2 2 0 0 2 2 2 2 2 1
26 I-1a 2 0 2 2 2 0 0 2 2 2 2 2
27 I-1b 2 2 2 2 2 0 2 2 2 2 2 1
28 I-1a 2 1 2 2 0 0 0 2 2 2 1 1
29 I-1a 2 0 0 2 0 0 2 2 2 2 1 1
30 I-1a 1 1 0 2 0 0 0 1 2 2 1 1
31 I-1b 1 2 2 2 2 2 2 2 2 2 2 1
32 II-1 1 1 0 2 0 0 0 2 2 2 1 1
   A B C D E F G H I J K L
Number of studies with maximum score 12 7 13 23 6 2 17 25 31 31 22 10
Percentage of studies with maximum score (%) 38 22 41 72 19 6 53 78 97 97 69 31
  1. Cochrane Bone, Joint and Muscle Trauma Group reporting quality assessment items:
  2. A. Was the assigned treatment adequately concealed prior to allocation?
  3. B. Were the outcomes of participants who withdrew described and included in the analysis (intention to treat)?
  4. C. Were the outcome assessors blinded to treatment status?
  5. D. Were the treatment and control group comparable at entry?
  6. E. Were the participants blind to assignment status after allocation?
  7. F. Were the treatment providers blind to assignment status?
  8. G. Were care programs, other than the trial options, identical?
  9. H. Were the inclusion and exclusion criteria clearly defined?
  10. I. Were the interventions clearly defined?
  11. J. Were the outcome measures used clearly defined?
  12. K. Were diagnostic tests used in outcome assessment clinically useful?
  13. L. Was the surveillance active, and of clinically appropriate duration?
  14. [See Additional file 1].